Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of osteoporosis and bone density, published as a randomized controlled trial.

Who Took Part

The study group was 841 subjects.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

This was a prospective, 12-month, randomized, open-labeled, actively controlled trial involving 41 hospitals.

What Was Measured

PubMed files the paper under topics including Absorptiometry, Photon, Alkaline Phosphatase, Bone Density, Bone Density Conservation Agents, Cholecalciferol, Femur Neck and Lumbar Vertebrae.

The authors tagged it with the keywords Bone mineral density, Osteoporosis and Risedronic acid.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 841 subjects in people with osteoporosis and bone density.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Archives of osteoporosis), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Osteoporosis and bone density research.